Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Compassionate use program of lurbinectedin

Next Previous
Trial Profile

Compassionate use program of lurbinectedin

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 22 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lurbinectedin (Primary)
  • Indications Breast cancer; Leiomyosarcoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Sarcoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
  • Focus Therapeutic Use

Most Recent Events

  • 14 Dec 2023 According to PharmaMar media release, based on data from this study Luye Pharma has received marketing approval for Zepzelca (lurbinectedin) by the Pharmacy and Poisons Board of the Hong Kong Special Administrative Region (SAR), for the treatment of adult patients with metastatic Small Cell Lung Cancer (SCLC) with disease progression upon or after receiving platinum-based chemotherapy. The FDA used the data of this study to grant accelerated approval for lurbinectedin.
  • 17 Jan 2023 New trial record
  • 09 Jan 2023 According to a PharmaMar media release, the company announced its partner in China Luye Pharma Group has launched this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top